Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCTNYSE:CYBNNASDAQ:PRQRNASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$1.22+8.5%$1.55$1.05▼$5.17$120.39M1.55620,935 shs307,151 shsCYBNCybin$6.80+18.5%$7.58$4.81▼$14.92$146.04M0.61227,270 shs560,075 shsPRQRProQR Therapeutics$1.12-0.9%$1.85$1.07▼$4.62$117.84M0.25577,576 shs762,681 shsRNTXRein Therapeutics$1.71+9.6%$1.97$1.35▼$7.42$37.05M2.1258,104 shs43,909 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics+8.00%+2.53%-35.20%-35.38%-73.87%CYBNCybin+18.47%+19.51%-7.36%-23.51%+1,544.50%PRQRProQR Therapeutics-0.88%-5.08%-39.46%-53.72%-50.44%RNTXRein Therapeutics+9.62%+0.59%-11.86%+170,999,900.00%+170,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics2.711 of 5 stars3.54.00.00.03.50.80.6CYBNCybin1.4214 of 5 stars3.50.00.00.00.00.81.3PRQRProQR Therapeutics1.6836 of 5 stars3.63.00.00.02.70.00.0RNTXRein TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75537.86% UpsideCYBNCybin 3.00Buy$86.001,164.71% UpsidePRQRProQR Therapeutics 3.17Buy$9.50748.21% UpsideRNTXRein Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest RNTX, PRQR, CYBN, and ADCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $7.003/31/2025ADCTADC TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.003/14/2025PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$10.00 ➝ $12.003/14/2025PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.003/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.003/10/2025PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.003/7/2025ADCTADC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight2/24/2025ADCTADC TherapeuticsStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$6.00 ➝ $8.002/13/2025CYBNCybinHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$190.00 ➝ $150.002/12/2025CYBNCybinCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $73.001/27/2025CYBNCybinHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$190.00 ➝ $190.00(Data available from 4/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M1.70N/AN/A($1.93) per share-0.63CYBNCybinN/AN/AN/AN/A$10.83 per shareN/APRQRProQR Therapeutics$18.91M6.23N/AN/A$0.55 per share2.04RNTXRein TherapeuticsN/AN/AN/AN/A$1.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$240.05M-$1.65N/AN/AN/A-300.00%N/A-61.33%5/5/2025 (Estimated)CYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/APRQRProQR Therapeutics-$30.43M-$0.34N/AN/AN/A-134.31%-71.58%-19.70%5/8/2025 (Estimated)RNTXRein Therapeutics-$15.73M-$3.47N/AN/AN/AN/A-74.08%-27.93%N/ALatest RNTX, PRQR, CYBN, and ADCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09N/AN/AN/A$4.90 millionN/A5/5/2025Q1 2025ADCTADC Therapeutics-$0.38N/AN/AN/A$17.71 millionN/A4/7/2025Q4 2024RNTXRein TherapeuticsN/A-$0.26N/A-$1.89N/AN/A3/27/2025Q4 2024ADCTADC Therapeutics-$0.35-$0.29+$0.06-$0.29$19.01 million$19.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACYBNCybinN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.924.68CYBNCybinN/A24.2424.24PRQRProQR TherapeuticsN/A2.332.33RNTXRein TherapeuticsN/A3.303.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%CYBNCybin17.94%PRQRProQR Therapeutics32.65%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics4.10%CYBNCybin15.00%PRQRProQR Therapeutics8.40%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics31099.08 million92.73 millionOptionableCYBNCybin5021.48 million17.96 millionNot OptionablePRQRProQR Therapeutics180105.21 million74.82 millionOptionableRNTXRein Therapeutics921.67 million20.56 millionN/ARNTX, PRQR, CYBN, and ADCT HeadlinesRecent News About These CompaniesRein Therapeutics, Inc.: Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 8, 2025 | finanznachrichten.deRein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateApril 7, 2025 | prnewswire.comRein Therapeutics Inc. (RNTX)March 25, 2025 | ca.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNTX, PRQR, CYBN, and ADCT Company DescriptionsADC Therapeutics NYSE:ADCT$1.22 +0.10 (+8.48%) Closing price 04/11/2025 03:59 PM EasternExtended Trading$1.21 0.00 (-0.08%) As of 04/11/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Cybin NYSE:CYBN$6.80 +1.06 (+18.47%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$6.82 +0.02 (+0.35%) As of 04/11/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.ProQR Therapeutics NASDAQ:PRQR$1.12 -0.01 (-0.88%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$1.16 +0.04 (+3.57%) As of 04/11/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.Rein Therapeutics NASDAQ:RNTX$1.71 +0.15 (+9.62%) As of 04/11/2025 04:00 PM EasternRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas JPMorgan is a Buy, if You Can Handle The Volatility Rocket Lab Stock: Weathering the Storm, Time for a Comeback? United States Steel's Crash: An Unmissable Buying Opportunity Micron Tumbles on Tariff Threat: Risk/Reward Outlook Improves Is Archer Aviation’s Stock Price Dip a Gift? Marvell Gets Tariff Lifeline But Expect More Volatility Snowflake Boosts Growth by Doubling Down on AI Broadcom's Big Outperformance Shows Strength Amid Tariff Decline Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
